Brand Insights - Thought Leadership | Paid Program | Fingerpaint Group
Integrating Payers Into Your Digital Communication Plan
Published: | Updated:
An evolving system requires a focus on digital channels
Why it’s important to integrate patient assistance programs for cell and gene therapies into the overall clinical development plan.
Resonating With the Emerging Gen Z HCP
Published: | Updated:
2020 is the year of reimagination.
Solving Access Challenges in Today’s Market
ByAndy Pyfer, Brand Insights Contributor, Partner, Fingerpaint,Roshawn Blunt, Brand Insights Contributor, Managing Director of 1798, a Fingerpaint company
Published: | Updated:
New drug launches face more marketplace scrutiny today than a decade ago. Brand success requires not only communicating the clinical value to providers and patients, but also demonstrating the cost-effectiveness to payers in a real-world setting.
How Rare Disease Marketing Will Stretch Beyond the Patient
ByLaura Wilson, Brand Insights Contributor, Patient Strategy, Fingerpaint,Jonathan Romeo, Brand Insights Contributor, Brand Strategy, Fingerpaint
Published: | Updated:
The foundation of a strong rare disease marketing program must be built on the comprehensive knowledge of how the life-altering disease impacts all areas of a patient’s life.
Three Technologies that Can Move Your Brand
Published: | Updated:
The rise of digital has enhanced our ability to personalize our marketing messages and engage our target audiences more effectively
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: FDA Approves Hernexeos
2
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
3
FDA Approves Hernexeos Under National Priority Voucher Program
4
FDA Approves Dupixent as First Treatment for Allergic Fungal Rhinosinusitis in Adults and Children
5